These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411 [TBL] [Abstract][Full Text] [Related]
3. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017 [TBL] [Abstract][Full Text] [Related]
4. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887 [TBL] [Abstract][Full Text] [Related]
5. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Nielsen S; Hillhouse M; Thomas C; Hasson A; Ling W J Addict Med; 2013; 7(1):33-8. PubMed ID: 23222095 [TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243 [TBL] [Abstract][Full Text] [Related]
7. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting. Amato P Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244 [TBL] [Abstract][Full Text] [Related]
8. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Chakrabarti A; Woody GE; Griffin ML; Subramaniam G; Weiss RD Drug Alcohol Depend; 2010 Mar; 107(2-3):253-6. PubMed ID: 19948382 [TBL] [Abstract][Full Text] [Related]
9. Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine. Saleh MI Eur Rev Med Pharmacol Sci; 2014; 18(24):3935-42. PubMed ID: 25555887 [TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564 [TBL] [Abstract][Full Text] [Related]
11. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255 [TBL] [Abstract][Full Text] [Related]
12. Participant characteristics and buprenorphine dose. Hillhouse M; Canamar CP; Doraimani G; Thomas C; Hasson A; Ling W Am J Drug Alcohol Abuse; 2011 Sep; 37(5):453-9. PubMed ID: 21854290 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre. Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241 [TBL] [Abstract][Full Text] [Related]
15. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675 [TBL] [Abstract][Full Text] [Related]
16. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Amass L; Kamien JB; Mikulich SK Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282 [TBL] [Abstract][Full Text] [Related]